Page last updated: 2024-12-11

(2-amino-5-chlorophenyl)(phenyl)methanone oxime

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

(2-amino-5-chlorophenyl)(phenyl)methanone oxime, often referred to as **AMCPO**, is a chemical compound that has attracted attention in research due to its potential applications in various fields.

**Structure and Properties:**

* **Molecular Formula:** C13H11ClN2O
* **Molecular Weight:** 262.7 g/mol
* **Appearance:** White to off-white solid
* **Solubility:** Soluble in organic solvents like ethanol and chloroform

**Research Significance:**

AMCPO has garnered research interest for several reasons:

1. **Antimicrobial Activity:** Studies have shown that AMCPO possesses significant antimicrobial activity against a range of bacteria, including **Staphylococcus aureus**, **Escherichia coli**, and **Pseudomonas aeruginosa**. This activity is attributed to its ability to interfere with the growth and replication of bacterial cells.

2. **Anti-inflammatory Properties:** AMCPO has also been investigated for its potential anti-inflammatory effects. Research suggests it may inhibit the production of pro-inflammatory mediators, potentially contributing to the reduction of inflammation.

3. **Antioxidant Activity:** Studies indicate that AMCPO possesses antioxidant properties. It can scavenge free radicals, protecting cells from oxidative stress, which is linked to various health issues.

4. **Drug Delivery:** AMCPO has been explored as a potential carrier for drug delivery. Its chemical structure allows it to bind to certain drugs, facilitating their transport to target sites within the body.

5. **Other Applications:** Research is ongoing to explore other potential applications of AMCPO, including its use in organic synthesis and material science.

**Current Research:**

Research into AMCPO is still ongoing, with researchers exploring its various biological activities, potential applications in drug development, and its impact on specific cellular processes. The aim is to fully understand its mechanism of action and optimize its properties for specific therapeutic or industrial uses.

**Note:** It's crucial to note that while research is promising, more studies are needed to fully understand the safety and efficacy of AMCPO for human use.

Cross-References

ID SourceID
PubMed CID5398630
CHEMBL ID3208177
CHEBI ID190626

Synonyms (32)

Synonym
4-chloro-2-[(hydroxyimino)(phenyl)methyl]aniline
smr000034150
MLS000078203
SR-01000414316-2
4-chloro-2-[(e)-(hydroxyimino)(phenyl)methyl]aniline
STK806178
AKOS000279605
HMS551D11
(2-amino-5-chlorophenyl)(phenyl)methanone oxime
(ne)-n-[(2-amino-5-chlorophenyl)-phenylmethylidene]hydroxylamine
CHEBI:190626
(e)-n-[(2-amino-5-chlorophenyl)-phenylmethylidene]hydroxylamine
benzophenone, 2-amino-5-chloro-, oxime
A812573
CCG-48409
(2-amino-5-chloro-phenyl)-phenyl-methanone oxime
(e)-(2-amino-5-chlorophenyl)(phenyl)methanone oxime #
GCAVNCINXJNLED-DTQAZKPQSA-N
W-109174
CHEMBL3208177
SR-01000414316-1
sr-01000414316
2-amino-5-chlorbenzophenonoxim
2-amino-5-chlorobenzophenone i+/--oxime-, (z)-
methanone, (2-amino-5-chlorophenyl)phenyl-, oxime, (e)-
A4AZJ6W4EQ
methanone, (2-amino-5-chlorophenyl)phenyl-, oxime, (1e)-
anti-2-amino-5-chlorobenzophenone oxime
2-amino-5-chlorobenzophenone oxime, (e)-
benzophenone, 2-amino-5-chloro-, oxime, (e)-
DTXSID901230398
(1e)-(2-amino-5-chlorophenyl)phenylmethanone oxime
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency11.22020.01846.806014.1254AID624417
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency14.12540.010323.856763.0957AID2662
survival motor neuron protein isoform dHomo sapiens (human)Potency11.22020.125912.234435.4813AID1458
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624287
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
FAD-linked sulfhydryl oxidase ALRHomo sapiens (human)AC5022.78700.00503.212622.7870AID493248
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (5)

Processvia Protein(s)Taxonomy
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]